A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells

Experimental Cell Research

Volumn 327, Issue 2, 2014, Pages 331-339

  Hatkevich, Talia ^a   Ramos, Joseph ^a   Santos Sanchez, Idalys ^a   Patel, Yashomati M ^a  

^a UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

Apoptosis; Breast cancer; Cell proliferation; Naringenin; Tamoxifen

Indexed keywords

CASPASE 7; CASPASE 9; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; NARINGENIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; FLAVANONE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CULTURE; CELL DENSITY; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN BINDING; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; BREAST TUMOR; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BREAST CANCER; CELL PROLIFERATION; NARINGENIN; TAMOXIFEN;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; ESTROGEN ANTAGONISTS; FEMALE; FLAVANONES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; PHOSPHORYLATION; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 84907699846     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.05.017     Document Type: Article

References (30)

1. DeSantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics, 2013. CA Cancer J. Clin. 2014, 64:52-62.
2. Deroo B.J., Korach K.S. Estrogen receptors and human disease. J. Clin. Investig. 2006, 116:561-570.
3. Safe S., Kim K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J. Mol. Endocrinol. 2008, 41:263-275.
4. Sommer S., Fuqua S.A. Estrogen receptor and breast cancer. Semin. Cancer Biol. 2001, 11:339-352.
5. Kumar V., Green S., Stack G., Berry M., Jin J.R., et al. Functional domains of the human estrogen receptor. Cell 1987, 51:941-951.
6. Bunone G., Briand P.A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15:2174-2183.
7. Driggers P.H., Segars J.H. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol. Metab. 2002, 13:422-427.
8. Ghayad S.E., Vendrell J.A., Ben Larbi S., Dumontet C., Bieche I., et al. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int. J. Cancer 2010, 126:545-562.
9. Baum M. Tamoxifen--the treatment of choice. Why look for alternatives? Br J Cancer 1998, 78(Suppl 4):S1-S4.
10. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2002, 2:101-112.
11. Sanchez C.G., Ma C.X., Crowder R.J., Guintoli T., Phommaly C., et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011, 13:R21.
12. Harmon A.W., Patel Y.M. Naringenin inhibits phosphoinositide 3-kinase activity and glucose uptake in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2003, 305:229-234.
13. Harmon A.W., Patel Y.M. Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation. Breast Cancer Res. Treat. 2004, 85:103-110.
14. Bulzomi P., Bolli A., Galluzzo P., Acconcia F., Ascenzi P., et al. The naringenin-induced proapoptotic effect in breast cancer cell lines holds out against a high bisphenol a background. IUBMB Life 2012, 64:690-696.
15. Galluzzo P., Ascenzi P., Bulzomi P., Marino M. The nutritional flavanone naringenin triggers antiestrogenic effects by regulating estrogen receptor alpha-palmitoylation. Endocrinology 2008, 149:2567-2575.
16. Totta P., Acconcia F., Leone S., Cardillo I., Marino M. Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling. IUBMB Life 2004, 56:491-499.
17. Virgili F., Acconcia F., Ambra R., Rinna A., Totta P., et al. Nutritional flavonoids modulate estrogen receptor alpha signaling. IUBMB Life 2004, 56:145-151.
18. Marino M., Pellegrini M., La Rosa P., Acconcia F. Susceptibility of estrogen receptor rapid responses to xenoestrogens: physiological outcomes. Steroids 2012, 77:910-917.
19. Bulzomi P., Bolli A., Galluzzo P., Leone S., Acconcia F., et al. Naringenin and 17beta-estradiol coadministration prevents hormone-induced human cancer cell growth. IUBMB Life 2010, 62:51-60.
20. Kurokawa H., Nishio K., Fukumoto H., Tomonari A., Suzuki T., et al. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. Oncol. Rep. 1999, 6:33-37.
21. Clemons M., Danson S., Howell A. Tamoxifen (Nolvadex): a review. Cancer Treat. Rev. 2002, 28:165-180.
22. Fox E.M., Arteaga C.L., Miller T.W. Abrogating endocrine resistance by targeting ERalpha and PI3K in breast cancer. Front. Oncol. 2012, 2:145.
23. Li J., Chen P., Sinogeeva N., Gorospe M., Wersto R.P., et al. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J. Biol. Chem. 2002, 277:49504-49510.
24. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270:1491-1494.
25. Kurokawa H., Lenferink A.E., Simpson J.F., Pisacane P.I., Sliwkowski M.X., et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000, 60:5887-5894.
26. Liang K., Jin W., Knuefermann C., Schmidt M., Mills G.B., et al. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol. Cancer Ther. 2003, 2:353-360.
27. Migliaccio A., Di Domenico M., Castoria G., de Falco A., Bontempo P., et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 1996, 15:1292-1300.
28. Sun M., Paciga J.E., Feldman R.I., Yuan Z., Coppola D., et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 2001, 61:5985-5991.
29. Tokunaga E., Kataoka A., Kimura Y., Oki E., Mashino K., et al. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur. J. Cancer 2006, 42:629-635.
30. Fan P., Wang J., Santen R.J., Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res. 2007, 67:1352-1360.